Growing validations indicated that the KRAS mutations may mainly produce an immunosuppressive TME by facilitating the development of immunomodulatory markers in tumor cells, including interleukin-6, transforming growth factor, and interleukin-10 [150]. The gene discussed is IL10; the disease is neoplasm.